Together we Drive the Future

CNS Diseases Summit

EARLY BIRD DISCOUNT! Register by Jul 11, 2017 to receive 20% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!

registration button

CNS Diseases Summit

Neurodegenerative Diseases Research & Development

CNS Partnering & Deal-Making

Subscribe for updates

Dear Colleague,

We are excited to announce the CNS Diseases Summit, to be held on September 11-12, 2017 in Boston, MA. This meeting provides an interactive learning and relationship-building forum for all players in the CNS field. Colleagues from industry, academia, government agencies, and financing bodies will gather at the interface of research, partnerships, funding, and commercialization to find ways to move forward in a field that has been troubled with clinical failures.

The program will provide a comprehensive look at the current state of CNS, from research to commercialization. Above all, this event will provide networking opportunities in an intimate and accessible environment.

We invite you to join us as we connect, build relationships, and seek new ways forward into the future of CNS research and development.

Session Topics:

Joint Plenary Sessions:
I. Kick-off Keynote Session – Historical Perspective & State of the Industry
II. Award Ceremony & Closing Keynote Session – Predictions for future
III. Round Table Session: Neuroimaging & Translational Biomarkers 

11th Neurodegenerative Diseases Research & Development
I. Experimental Therapeutics & Approaches in Alzheimer’s Disease
II. Advances in Parkinson’s Disease Research & Therapeutics
III. Next Frontier in Multiple Sclerosis to Limit or Reverse Neurodegeneration
IV. Therapeutics for Rare & Orphan Neurodegenerative Diseases

10th CNS Partnering & Deal-making
I. What sells in CNS – New Targets, Models, Assays, etc.
II. Partnering with Academia & CROs to Advance Research
III. CNS Perspectives from Venture Capital & Public Markets
IV. Technology Transfer & Licensing: Challenges & Opportunities

We hope to see you there!


Best regards,

The 2017 Advisory Committee